Natilie Hosea

2.5k citations

21 papers · 1.5k indexed · h-index 16

Pharmacology top 0.5%
Oncology top 5%
Molecular Biology
Pharmacology top 2%
Computational Theory and Mathematics top 2%

Co-authors: F. Peter Guengerich Palmer Taylor Harvey Alan Berman Grover P. Miller Zoran Radić Bill J. Smith Megan Gibbs Hannah M. Jones
Topics: Pharmacogenetics and Drug Metabolism (10 papers)Computational Drug Discovery Methods (7 papers)Cholinesterase and Neurodegenerative Diseases (5 papers)
Cited by: Pharmacology Oncology
Journals: Journal of Clinical Oncology Biochemistry Journal of Pharmacology and Experimental Therapeutics
Partner nations: United States United Kingdom Japan

In The Last Decade

Natilie Hosea

21 papers receiving 1.5k citations

Peers

Countries citing papers authored by Natilie Hosea

Since Specialization

Citations

This map shows the geographic impact of Natilie Hosea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natilie Hosea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natilie Hosea more than expected).

Fields of papers citing papers by Natilie Hosea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natilie Hosea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natilie Hosea. The network helps show where Natilie Hosea may publish in the future.

Co-authorship network of co-authors of Natilie Hosea

This figure shows the co-authorship network connecting the top 25 collaborators of Natilie Hosea. A scholar is included among the top collaborators of Natilie Hosea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natilie Hosea. Natilie Hosea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Intermittent Oral Coadministration of a Gamma Secretase Inhibitor with Dexamethasone Mitigates Intestinal Goblet Cell Hyperplasia in Rats 2013 ·Toxicologic Pathology ·Shirley A. Aguirre,Ling Liu,Natilie Hosea,(unknown),(unknown),Leigh Ann Burns‐Naas,Sophia Randolph,Robert H. Denlinger,Bora Han	4
2	Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding 2012 ·BMC Genomics ·Zhou Zhu,(unknown),Wenyue Hu,Heather Estrella,(unknown),Tim Nichols,David M. Briere,Natilie Hosea,Gerrit Los,Paul A. Rejto,Andrea Fanjul	7
3	Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer 2011 ·Bioorganic & Medicinal Chemistry Letters ·Chuangxing Guo,Susan E. Kephart,Martha A. Ornelas,Javier González,Angelica Linton,Mason Pairish,Asako Nagata,S.E. Greasley,Jeff Elleraas,Natilie Hosea,(unknown),Andrea Fanjul	11
4	Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling 2011 ·Clinical Pharmacokinetics ·Hannah M. Jones,Iain Gardner,Wendy T. Collard,Phil Stanley,(unknown),Natilie Hosea,David R. Plowchalk,(unknown),Jing Lin,Maurice Dickins,(unknown),Barry Jones,Kenny J. Watson,Henry Pertinez,Vikas Kumar,Susan Cole	79
5	Drug Design Tools - In Silico, In Vitro and In Vivo ADME/PK Prediction and Interpretation: Is PK in Monkey An Essential Part of a Good Human PK Prediction? 2011 ·Current Topics in Medicinal Chemistry ·Natilie Hosea	3
6	Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors. 2011 ·Journal of Clinical Oncology ·Suzanne F. Jones,Geoffrey I. Shapiro,Johanna C. Bendell,(unknown),(unknown),(unknown),Shuchi S. Pandya,Kristen J. Pierce,Brett E. Houk,Natilie Hosea,(unknown),(unknown),S. Martin Shreeve,Lillian L. Siu	10
7	Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design 2010 ·Molecular Cancer Therapeutics ·Ping Wei,Marlena Walls,Ming Qiu,(unknown),Robert H. Denlinger,Anthony Wong,(unknown),Jitesh P. Jani,Natilie Hosea,Michelle Sands,Sophia Randolph,Tod Smeal	158
8	N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275 2009 ·Bioorganic & Medicinal Chemistry Letters ·Michael Siu,Theodore Johnson,Yong Wang,Sajiv K. Nair,(unknown),(unknown),(unknown),Martin P. Edwards,Thomas Pauly,Jacques Ermolieff,(unknown),Natilie Hosea,(unknown),Andrea Fanjul,(unknown)	35
9	Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches 2009 ·The Journal of Clinical Pharmacology ·Natilie Hosea,Wendy T. Collard,Susan Cole,Tristan S. Maurer,(unknown),Hannah M. Jones,Shefali Kakar,Yasuhiro Nakai,Bill J. Smith,Rob Webster,Kevin Beaumont	205
10	Demonstration of Proof of Mechanism and Pharmacokinetics and Pharmacodynamic Relationship with 4′-Cyano-biphenyl-4-sulfonic Acid (6-Amino-pyridin-2-yl)-amide (PF-915275), an Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1, in Cynomolgus Monkeys 2007 ·Journal of Pharmacology and Experimental Therapeutics ·Balkrishen Bhat,Natilie Hosea,Andrea Fanjul,(unknown),(unknown),(unknown),Paul M. Stewart,Paul A. Rejto	47
11	Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration 2006 ·Drug Metabolism and Disposition ·Xingrong Liu,Bill J. Smith,Cuiping Chen,Ernesto Callegari,Stacey L. Becker,Xi Chen,Julie Cianfrogna,Angela C. Doran,Shawn D. Doran,John P. Gibbs,Natilie Hosea,Jianhua Liu,Frederick Nelson,(unknown),(unknown)	129
12	Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding 2005 ·Journal of Pharmacology and Experimental Therapeutics ·Xingrong Liu,Bill J. Smith,Cuiping Chen,Ernesto Callegari,Stacey L. Becker,Xi Chen,Julie Cianfrogna,Angela C. Doran,Shawn D. Doran,John P. Gibbs,Natilie Hosea,Jianhua Liu,Frederick Nelson,(unknown),(unknown)	136
13	Factors Affecting the Clinical Development of Cytochrome P450 3A Substrates 2003 ·Clinical Pharmacokinetics ·Megan Gibbs,Natilie Hosea	49
14	Elucidation of Distinct Ligand Binding Sites for Cytochrome P450 3A4 2000 ·Biochemistry ·Natilie Hosea,Grover P. Miller,F. Peter Guengerich	201
15	Analysis of cholinesterase inactivation and reactivation by systematic structural modification and enantiomeric selectivity 1999 ·Chemico-Biological Interactions ·Palmer Taylor,Lilly Wong,Zoran Radić,Igor F. Tsigelny,Roger J. M. Brüggemann,Natilie Hosea,Harvey Alan Berman	20
16	Oxidation of Nonionic Detergents by Cytochrome P450 Enzymes 1998 ·Archives of Biochemistry and Biophysics ·Natilie Hosea,F. Peter Guengerich	32
17	Reconstitution Premixes for Assays Using Purified Recombinant Human Cytochrome P450, NADPH-Cytochrome P450 Reductase, and Cytochromeb5 1997 ·Archives of Biochemistry and Biophysics ·Peter Shaw,Natilie Hosea,David V. Thompson,(unknown),F. Peter Guengerich	80
18	Aspartate 74 as a Primary Determinant in Acetylcholinesterase Governing Specificity to Cationic Organophosphonates 1996 ·Biochemistry ·Natilie Hosea,Zoran Radić,Igor F. Tsigelny,Harvey Alan Berman,Daniel M. Quinn,Palmer Taylor	60
19	Structural bases for the specificity of cholinesterase catalysis and inhibition 1995 ·Toxicology Letters ·Palmer Taylor,Zoran Radić,Natilie Hosea,Shelley Camp,P. Marchot,Harvey Alan Berman	83
20	Specificity and Orientation of Trigonal Carboxyl Esters and Tetrahedral Alkylphosphonyl Esters in Cholinesterases 1995 ·Biochemistry ·Natilie Hosea,Harvey Alan Berman,Palmer Taylor	87

About Natilie Hosea

Natilie Hosea is a scholar working on Pharmacology, Computational Theory and Mathematics and Pharmacology, having authored 21 papers that have together received 1.5k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (10 papers), Computational Drug Discovery Methods (7 papers) and Cholinesterase and Neurodegenerative Diseases (5 papers). The work is most often cited by research in Pharmacology (549 citations), Pharmacology (414 citations) and Oncology (487 citations). Natilie Hosea has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include F. Peter Guengerich, Palmer Taylor, Harvey Alan Berman, Grover P. Miller, Zoran Radić, Bill J. Smith, Megan Gibbs, Hannah M. Jones, Susan Cole and Wendy T. Collard. Their work appears in journals such as Journal of Clinical Oncology, Biochemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact